Your browser is no longer supported. Please, upgrade your browser.
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-9.78 Insider Own14.20% Shs Outstand32.99M Perf Week-11.71%
Market Cap907.77M Forward P/E- EPS next Y-6.45 Insider Trans-48.96% Shs Float27.80M Perf Month-13.11%
Income-320.90M PEG- EPS next Q-1.49 Inst Own89.10% Short Float23.45% Perf Quarter-20.81%
Sales300.90M P/S3.02 EPS this Y-0.20% Inst Trans0.15% Short Ratio6.54 Perf Half Y-43.77%
Book/sh-3.95 P/B- EPS next Y20.90% ROA-48.50% Target Price54.13 Perf Year-75.10%
Cash/sh14.84 P/C1.85 EPS next 5Y-8.89% ROE667.70% 52W Range23.78 - 114.66 Perf YTD11.13%
Dividend- P/FCF- EPS past 5Y4.40% ROI-53.50% 52W High-76.06% Beta1.75
Dividend %- Quick Ratio3.40 Sales past 5Y170.50% Gross Margin97.70% 52W Low15.41% ATR2.06
Employees583 Current Ratio3.40 Sales Q/Q28.20% Oper. Margin-93.00% RSI (14)41.78 Volatility5.89% 6.97%
OptionableYes Debt/Eq- EPS Q/Q22.30% Profit Margin- Rel Volume2.59 Prev Close29.24
ShortableYes LT Debt/Eq- EarningsNov 09 BMO Payout- Avg Volume996.71K Price27.45
Recom2.50 SMA20-3.48% SMA50-14.96% SMA200-46.16% Volume2,578,713 Change-6.12%
Jan-15-21Downgrade BofA Securities Neutral → Underperform $40 → $27
Dec-21-20Downgrade Jefferies Buy → Hold $30
Nov-10-20Upgrade Robert W. Baird Neutral → Outperform $52
Nov-10-20Upgrade Raymond James Mkt Perform → Outperform $60
Jul-31-20Initiated Piper Sandler Overweight $82
Jul-21-20Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-30-20Upgrade Citigroup Neutral → Buy
Jun-30-20Downgrade UBS Buy → Neutral $135 → $57
Jun-30-20Downgrade Robert W. Baird Outperform → Neutral $52
Jun-30-20Downgrade Credit Suisse Outperform → Neutral $137 → $59
Jun-30-20Downgrade Cowen Outperform → Market Perform $47
Jun-30-20Downgrade Cantor Fitzgerald Overweight → Neutral
Jun-29-20Downgrade Wells Fargo Overweight → Equal Weight
Jun-29-20Downgrade RBC Capital Mkts Outperform → Sector Perform $117 → $55
Jun-29-20Downgrade Oppenheimer Outperform → Perform
Jun-29-20Downgrade Goldman Buy → Neutral $150 → $60
Jun-29-20Downgrade Canaccord Genuity Buy → Hold
Jun-29-20Downgrade BMO Capital Markets Outperform → Market Perform $107 → $52
Jun-25-20Initiated H.C. Wainwright Neutral $92
Jun-05-20Initiated BMO Capital Markets Outperform $107
Jan-11-21 08:00AM  
Jan-05-21 08:00AM  
Jan-04-21 12:45PM  
11:53AM  
11:45AM  
11:12AM  
09:47AM  
09:31AM  
09:15AM  
08:30AM  
06:20AM  
Jan-03-21 11:45PM  
12:10PM  
11:00AM  
10:30AM  
Jan-02-21 11:19PM  
04:00PM  
Jan-01-21 09:00PM  
07:15PM  
Dec-31-20 03:00PM  
02:12PM  
01:40PM  
12:42PM  
12:40PM  
11:45AM  
11:40AM  
Dec-30-20 02:40PM  
01:55PM  
10:30AM  
10:00AM  
10:00AM  
Dec-29-20 02:30PM  
01:15PM  
11:45AM  
11:00AM  
07:30AM  
Dec-28-20 10:28PM  
09:00PM  
08:45PM  
08:15PM  
01:20PM  
12:30PM  
12:00PM  
11:00AM  
10:20AM  
10:18AM  
Dec-26-20 03:07PM  
Dec-24-20 04:35PM  
03:56PM  
06:19AM  
Dec-23-20 09:50PM  
04:28PM  
03:00PM  
11:30AM  
11:00AM  
Dec-22-20 05:30PM  
05:00PM  
01:25PM  
12:47PM  
12:00PM  
11:30AM  
11:25AM  
06:19AM  
12:40AM  
Dec-21-20 07:35PM  
03:22PM  
01:54PM  
12:30PM  
12:00PM  
11:00AM  
06:10AM  
Dec-19-20 10:10PM  
05:58PM  
08:35AM  
Dec-18-20 04:55PM  
04:15PM  
01:20PM  
12:30PM  
12:00PM  
11:21AM  
Dec-17-20 01:35PM  
01:00PM  
12:00PM  
11:30AM  
06:30AM  
Dec-16-20 11:30PM  
06:30PM  
06:00PM  
03:45PM  
02:45PM  
Dec-15-20 06:45PM  
04:03PM  
04:00PM  
03:01PM  
02:32PM  
01:00PM  
12:33PM  
11:00AM  
10:45AM  
10:12AM  
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kapadia SandipCFO and TreasurerJan 05Sale24.472,19353,66323,764Jan 05 07:01 PM
Kapadia SandipCFO and TreasurerDec 15Sale32.781,76357,79127,158Dec 16 07:00 PM
Campagna JasonChief Medical OfficerAug 18Sale47.441,19256,5438,778Aug 20 07:00 PM
Micheli Francesco10% OwnerAug 17Sale47.071,362,40064,123,0994,000,000Aug 17 08:10 PM
Fundaro PaoloDirectorAug 17Sale47.071,362,40064,123,0994,000,000Aug 17 08:06 PM
Genextra S.p.A.10% OwnerAug 17Sale47.071,362,40064,123,0994,000,000Aug 17 08:13 PM
Genextra S.p.A.10% OwnerAug 14Sale50.5554,6002,760,1125,362,400Aug 17 08:13 PM
Fundaro PaoloDirectorAug 14Sale50.5554,6002,760,1125,362,400Aug 17 08:06 PM
Micheli Francesco10% OwnerAug 14Sale50.5554,6002,760,1125,362,400Aug 17 08:10 PM
Micheli Francesco10% OwnerAug 13Sale52.6083,0004,365,4515,417,000Aug 17 08:10 PM
Fundaro PaoloDirectorAug 13Sale52.6083,0004,365,4515,417,000Aug 17 08:06 PM
Genextra S.p.A.10% OwnerAug 13Sale52.6083,0004,365,4515,417,000Aug 17 08:13 PM
Fundaro PaoloDirectorMay 13Sale84.60595,57850,385,8995,500,000May 15 05:19 PM
Micheli Francesco10% OwnerMay 13Sale84.60595,57850,385,8995,500,000May 15 04:55 PM
Genextra S.p.A.10% OwnerMay 13Sale84.60595,57850,385,8995,500,000May 15 04:46 PM
Weyer ChristianEVP, Research & DevelopmentApr 27Sale85.9518115,55717,140Apr 29 07:00 PM
Ford David AChief Human Resources OfficerApr 09Sale70.00584,06013,882Apr 10 07:00 PM
Weyer ChristianEVP, Research & DevelopmentFeb 27Sale87.621139,90117,367Feb 28 07:00 PM
Weyer ChristianEVP, Research & DevelopmentJan 27Sale94.0472367,99117,837Jan 27 07:01 PM